IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits improved potency and in vivo half-life: Potential application in combination with broad neutralizing antibodies

The clinical application of conventional peptide drugs, such as the HIV-1 fusion inhibitor enfuvirtide, is limited by their short half-life in vivo. To overcome this limitation, we developed a new strategy to extend the in vivo half-life of a short HIV-1 fusion inhibitory peptide, CP24, by fusing it...

Descripción completa

Detalles Bibliográficos
Autores principales: Bi, Wenwen, Xu, Wei, Cheng, Liang, Xue, Jing, Wang, Qian, Yu, Fei, Xia, Shuai, Wang, Qi, Li, Guangming, Qin, Chuan, Lu, Lu, Su, Lishan, Jiang, Shibo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894747/
https://www.ncbi.nlm.nih.gov/pubmed/31805154
http://dx.doi.org/10.1371/journal.ppat.1008082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894747/
https://www.ncbi.nlm.nih.gov/pubmed/31805154
http://dx.doi.org/10.1371/journal.ppat.1008082

Ejemplares similares